496 related articles for article (PubMed ID: 18414808)
1. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
[TBL] [Abstract][Full Text] [Related]
2. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.
Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ
Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
4. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S
Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169
[TBL] [Abstract][Full Text] [Related]
5. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil.
Cerci JJ; Pracchia LF; Soares Junior J; Linardi Cda C; Meneghetti JC; Buccheri V
Clinics (Sao Paulo); 2009; 64(6):491-8. PubMed ID: 19578651
[TBL] [Abstract][Full Text] [Related]
7. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.
Bangerter M; Moog F; Buchmann I; Kotzerke J; Griesshammer M; Hafner M; Elsner K; Frickhofen N; Reske SN; Bergmann L
Ann Oncol; 1998 Oct; 9(10):1117-22. PubMed ID: 9834825
[TBL] [Abstract][Full Text] [Related]
8. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
[TBL] [Abstract][Full Text] [Related]
9. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
[TBL] [Abstract][Full Text] [Related]
10. Utility of
Jitani AK; Dutta S; Mandal PK; De R; Jajodia E; Baul S; Chakrabarti P; Dolai TK
Indian J Med Res; 2021 May; 154(5):691-698. PubMed ID: 35532587
[TBL] [Abstract][Full Text] [Related]
11. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
12. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
[TBL] [Abstract][Full Text] [Related]
13. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
Ömür Ö; Baran Y; Oral A; Ceylan Y
Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study.
Pelosi E; Penna D; Douroukas A; Bellò M; Amati A; Arena V; Passera R; Bisi G
Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):469-75. PubMed ID: 21150862
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
16. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M
Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364
[TBL] [Abstract][Full Text] [Related]
17. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
[TBL] [Abstract][Full Text] [Related]
18. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging.
Lopci E; Burnelli R; Ambrosini V; Nanni C; Castellucci P; Biassoni L; Rubello D; Fanti S
Cancer Biother Radiopharm; 2008 Dec; 23(6):681-90. PubMed ID: 19111053
[TBL] [Abstract][Full Text] [Related]
19. Staging in childhood lymphoma: differences between FDG-PET and CT.
Hermann S; Wormanns D; Pixberg M; Hunold A; Heindel W; Jürgens H; Schober O; Franzius C
Nuklearmedizin; 2005 Feb; 44(1):1-7. PubMed ID: 15711722
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma.
Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P
Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
